Novavax statement on prototype vaccine’s broad immune responses and accelerated focus on Omicron BA.4/5 as recommended by the FDA.
Novavax is awaiting US emergency use authorization for its prototype COVID-19 vaccine and is committed to bringing it to market. Clinical data generated to-date demonstrate that this prototype vaccine offers broad immune responses including against circulating variants, such as the Omicron BA.4/5.
Novavax is already well underway in its variant program and will accelerate its focus on Omicron BA.4/5, as recommended by FDA in their guidance on June 30th. The company expects to have additional preclinical data on Omicron BA.4/5 in the late summer or fall, and expect to be in a position to provide an Omicron-containing vaccine in Q4 of this year.
Novavax continues to believe in the importance of vaccines that offer broad immune responses against a variety of variants, given the fact that COVID-19 will continue to evolve.
Related news and insights
Roche announced that the FDA has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumours have activating HER2 (ERBB2) mutations, as detected by a FDA-approved test, and who have received a prior systemic therapy
The Menarini Group announced that the FDA has accepted the Company’s New Drug Application (NDA) for elacestrant, an investigational selective estrogen receptor degrader (SERD), for patients with ER+/HER2- advanced or metastatic breast cancer.